Half of Adults 50 and Younger With Low 10-Year Risk of CVD Have High Lifetime Risk

American Heart Association rapid access journal report Study highlights: A traditional scoring method to determine the odds of having cardiovascular disease within 10 years may not be sufficient for risk estimation. Most adults 50 years and younger have a low 10-yea...

A simplified scoring system may predict overall CVD risk, individual CVD components risk

Physicians currently evaluate a patients risk for heart disease, stroke and other cardiovascular diseases (CVD) individually, but a new assessment tool could gauge risk of overall ,or global, CVD and a range of cardiovascular diseases at one time, according to a study published in Circulation: Jou...

Covance to Acquire Seattle-Based Gene Expression Laboratory from Merck & Co., Inc.

... PRINCETON, N.J., July 29 /PRNewswire-FirstCall/ -- Covance (NYSE: cvd ) today announced it has entered into a definitive agreement with Merck & Co., Inc. relating to the supply of genomic analysis services. Under the...

Covance Reports Second Quarter Revenue of $466M and EPS of $0.66

... PRINCETON, N.J., July 29 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE: cvd ) today reported GAAP earnings for its second quarter ended June 30, 2009 of $0.67 per diluted share, inclusive of a $0.01 per share gain related to t...

NBCH Releases Report on Health Plans' Performance for Cardiovascular Disease Care and Prevention

... encourage adherence to treatment. For patients on cvd medications, 85 percent of plans are capable of al... Ohio. "The real issue is that once employees have cvd it's often late in the process of the disease. We ...tion, exercise, and weight management, to head off cvd before it causes a debilitating problem." ...

Oral/body inflammatory connection explained

...on adults (1 out of every 3) have been a victim of cvd in 2006 according to the American Heart Associatio...en their belief that oral infections contribute to cvd morbidity and connection of chronic infections and...at many, if not most, patients are unaware of." cvd has a wide range of categories, which affect adult...

Covance Inc. Invites You to Join the Webcast of Its Second Quarter 2009 Financial Results Conference Call

...ll/ -- In conjunction with its second quarter 2009 earnings release (expected to be issued after market close on July 29, 2009), Covance Inc. (NYSE: cvd ) is pleased to invite you to listen to its quarterly investor conference call that will be broadcast live over the Internet on Thursday, July 30, 200...

Patients with moderate to severe periodontitis need evaluation for heart disease risk

...odontitis are at increased risk of atherosclerotic cvd the accumulation of lipid products within the art...the link between periodontitis and atherosclerotic cvd is not yet clear, but a leading candidate is infla...explanations for periodontitis and atherosclerotic cvd are common risk factors such as smoking, diabetes ...

BioInformatics, LLC New Report - Exploring the Epigenetics Market: Opportunities for Product Placement and Innovations

...m (EMD) (NYSE: EMD ) Caltag (life Technologies) Cell Signaling Technology Chemicon International (Millipore) (NYSE: MIL ) Covance (NYSE: cvd ) Dako Diagenode Dynal Biotech (Life Technologies) eBioscience Endogen (Thermo Fisher Scientific) GE Healthcare (Amersham) (NYSE: GE ) ...

Covance to Present at Goldman Sachs Thirtieth Annual Global Healthcare Conference

... PRINCETON, N.J., June 10 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE: cvd ) today announced that it will present at Goldman Sachs Thirtieth Annual Global Healthcare Conference on Thursday, June 11, 2009 at 10:20 a.m. (ET). ...

CVD in Medical Technology

Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results

... decreased from 32 to 11 percent and from 9 to 2 percent, respectively. ROADMAP was designed to allow analysis of BP responses and potential renal and cvd risk benefits across a wide range of patients with diabetes classified from normotension to hypertension, and to test whether this extensive subgroupi...

Diabetes Patients with High Triglycerides and Low HDL Cholesterol Get the Most Benefit From Fenofibrate Treatment: New Data From the FIELD Study

...ch Hospital, New Zealand, said: This 27% relative reduction in total cvd events with fenofibrate in type 2 diabetes patients with marked atherogenic...eatest clinical benefit from fenofibrate treatment, with a 27% reduction in cvd risk (from 17.8% to 13.5%, P=0.005). This risk was almost two-fold (29.8%) ...

Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society

...This symposium is supported by an unrestricted educational grant from Amylin Pharmaceuticals. 9. Corporate-sponsored symposium: "Reducing cvd Risk: Emerging Science and Therapeutic Options in the Management of Obesity and Type 2 Diabetes." This medical education symposium will help...

Volcano's VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKline's Novel Investigational Compound, Darapladib

...ls alone," said Scott Huennekens, President and CEO, Volcano Corp. "The ability to identify and characterize composition may lead to great advances in cvd drug development, diagnosis, and eventually tailored systemic therapy. The same way a biopsy and other blood and imaging tests can define a cancer tre...

TRANSCEND(TM) Trial Results Presented at European Society of Cardiology Congress and Published in The Lancet

...ide -- an estimated 17 million people per year.(8) cvd causes more deaths than cancer, chronic respirator...iabetes combined.(9) By 2020, it is predicted that cvd will surpass infectious diseases to become the lar...alating costs of health care. In 2006, the cost of cvd in the U.S. was estimated at $403.1 billion.(11) ...

ViaViente Demonstrates Cardiovascular Benefits in New Human Trial

...80 million people in the United States have CVD; nearly 2,400 people die of cvd every day; more people die from cvd than from cancer, auto accidents, and Type 2 diabetes combined; an estimate...

Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation

... with academic institutions and healthcare professionals, we are a major contributor in the effort to reduce the public health burden across the broad cvd spectrum and in thrombosis. About sanofi-aventis Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes ther...

Landmark ONTARGET(TM) Trial Demonstrates Micardis(R) is Equally Effective as Ramipril, with Fewer Discontinuations, in a Broad High-Risk Cardiovascular Population

...ide -- an estimated 17 million people per year.(5) cvd causes more deaths than cancer, chronic respirator...iabetes combined.(6) By 2020, it is predicted that cvd will surpass infectious diseases to become the lar...alating costs of health care. In 2006, the cost of cvd in the U.S. was estimated at $403.1 billion.(8) ...

Statement from the American Diabetes Association Related to ACCORD Trial Announcement

...sue. However, at this time, the American Diabetes Association advises people with diabetes who have existing cardiovascular disease (CVD), or multiple cvd risk factors, to consult with their health care team about their treatment goals and to ensure that their blood pressure and cholesterol are appropria...

Recent Findings from the Framingham Offspring Study Show Low Numbers of LDL Particles (LDL-P) by NMR are Associated With Fewer Heart Disease Related Events than Equivalently Low Levels of LDL Cholesterol (LDL-C).(1)

...VD). In this study, LDL-P was shown to be a more sensitive indicator of low cvd risk than LDL-C or non-HDL-C, another potential treatment target. The study... importance of managing patients to acceptably low levels of LDL-P to avoid cvd related events such as heart attack. Data in over 100 published papers re...

CVD in Medical Products

Clear Cornea 2.8mm Angled CVD Diamond

Description: Rhein Medical announces its new CVD Diamond Knives. New advancements in diamond technology allow the incredible sharpness of diamonds to be used at a more economical cost. Proven diamond blade sharpness improves stromal reapproximation, enhances healing, and insures a superior postoperative result....
Company:Rhein Medical, Inc.

Trapezoid 2.5-3.5mm Angled CVD Diamond

Description: New advancements in diamond technology allow the incredible sharpness of diamonds to be used at a more economical cost. Proven diamond blade sharpness improves stromal reapproximation, enhances healing, and insures a superior postoperative result. The knives offer unlimited uses, and are available ...
Company:Rhein Medical, Inc.

Needle Holder Delicate, Cvd w/o lock

Description: Needle holder, delicate, curved without lock...
Company:Boss Instruments, Ltd.

Micro Scissors Cvd

Description: Microscopic scissors, curved...
Company:ASSI

Micro Needle Holder, Cvd

Description: Microscopic needle holder, curved...
Company:ASSI

Sleep Centers

Features:...coring and analysis assistance and billing/collections New/Additional revenue source A MedCath managed cardiac sleep center will ensure that your cvd patients are screened for SDB and diagnosed, treated and managed for this important cormorbidity. MedCath can also demonstrate the advantages of cre...
Company:MedCath Corporation

More>>

CVD in Biological News

Laughter remains good medicine

...titled Mirthful Laughter, As Adjunct Therapy in Diabetic Care, Increases HDL Cholesterol and Attenuates Inflammatory Cytokines and hs-CRP and Possible cvd Risk. They will present the findings at the 122nd Annual Meeting of the American Physiological Society (APS; www.the-aps.org/press ), which is part ...

Laughter remains good medicine

...titled Mirthful Laughter, As Adjunct Therapy in Diabetic Care, Increases HDL Cholesterol and Attenuates Inflammatory Cytokines and hs-CRP and Possible cvd Risk. They will present the findings at the 122nd Annual Meeting of the American Physiological Society (APS; www.the-aps.org/press ), which is part ...

Researchers study how pistachios may improve heart health

...nces in pistachios, perhaps phytosterols and fiber. "Our study has shown that pistachios, eaten with a heart healthy diet, may decrease a person's cvd risk profile, says Penny Kris-Etherton, distinguished professor of nutrition and primary investigator of the study." ...

New study casts further doubt on risk of death from higher salt intake

...cial low-salt diet. After adjusting for known cvd risk factors, such as smoking, diabetes and blood ...odium were found to be 80% more likely to die from cvd compared to the one-fourth of the sample consuming...endently associated with higher risk of death from cvd or all other causes of death, says Dr. Hillel W. C...

Nutrition research unveiled this week shows pistachios are smart for the heart

...inent cardiovascular disease (CVD) risk factor. cvd remains the number one cause of death in the U.S.,...s, looked at the effects of pistachios on multiple cvd risk factors, some of which include cholesterol, b...l effects of a diet rich in pistachios on multiple cvd risk factors. As indicated in a previous release o...

Genetic variants of USF1 are associated with the increased risk for cardiovascular disease

...hile some of the genes involved in the etiology of cvd are known, many are yet to be discovered. During t...cription factor 1 (USF1) gene locus in relation to cvd risk factors, atherosclerosis, and incidence and p...ined association between USF1 variants and several cvd risk factors, such as lipid phenotypes, body compo...

LDL particle measurement by NMR recognized by ADA, ACC

...not be the best way to quantify a patients risk for cardiovascular disease (CVD). Cardiometabolic Risk (CMR) is associated with Type 2 Diabetes and cvd obesity, insulin resistance, hyperglycemia and hypertension are risk factors that often cluster together. ApoB and LDL particle concentration appear...

Simple screening questionnaire for kidney disease outperforms current clinical practice guidelines

...nce because of the use of additional variables, different weights for age groups, and questions about underlying CVD. Indeed, most CKD patients die of cvd before reaching end-stage renal disease (ESRD). Currently, researchers are trying to understand a potential bi-directional relationship between CKD an...

Highlights from the February 2008 Journal of the American Dietetic Association

...been identified that affect (cardiovascular disease) risk factors, the researchers write. An individualized dietary pattern is recommended to optimize cvd risk factor reduction while meeting nutrient needs. The review identifies effective dietary considerations including a diet that: Is low is satu...

Another type of nanotube, a how-to guide to making bamboo-structured carbon nanotubes

...he amount of copper present in the catalyst. These results challenge accepted wisdom that significant yields of CNTs can only be formed from catalytic cvd routes if first row or mid-row transition elements are used as catalysts. The article is available to view in its entirety on AZoJono at http://ww...

CVD in Biological Technology

Covance to Sell Its Interactive Voice and Web Response Services and Enter Into a Multi-Year Marketing Agreement with Phase Forward

... PRINCETON, N.J., July 15 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE: cvd ) today announced it has signed an agreement to sell its Interactive Voice & Web Response Services (IVRS/IWRS) business to Phase Forward (Nasdaq: ...

Covance Elects John McCartney to Company's Board of Directors

... PRINCETON, N.J., May 7 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE: cvd ) announced that it has elected John McCartney to its board of directors. Mr. McCartney currently serves as chairman of the board of A.M. Castle...

Covance Reports First Quarter Revenue of $441M and EPS of $0.63; Updates Full Year Financial Targets

... PRINCETON, N.J., April 29 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE: cvd ) today reported earnings for its first quarter ended March 31, 2009 of $0.63 per diluted share versus $0.76 per diluted share in the first quarter of...

Athera Signs Agreements With German and UK Distributors for New Cardiovascular Biomarker

...lopment of the broader clinical utility of our new cvd biomarker. We are looking forward to work with the...at low anti-PC levels predict an increased risk of cvd were presented. One study included myocardial infa...uld be used to predict the likelihood of secondary cvd events up to six months after an initial event. Th...

Covance Opens New Clinical Development Offices in Chile, Peru and Expands Argentina Office

... to reduce drug development timelines for biopharmaceutical companies - PRINCETON, N.J., April 7 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE: cvd ) today announced the recent opening of new clinical development offices in Santiago, Chile, and Lima, Peru, and the expansion of the company's Buenos...

New Discoveries on a Fingertip Test for Screening Silent Heart Disease Promising Results of Recent Clinical Studies to be Presented during the 2009 American College of Cardiology Conference, March 29th - April 1st in Orlando

...he inadequacy of existing methods of monitoring patients' response to treatments (Problem 2). Current methods for screening and early detection of cvd include blood tests for measurement of traditional risk factors (such as high cholesterol) or advanced, non-invasive imaging techniques such as CAT sc...

Jina Ventures Advises Swiss Pharma Contract on Strategic Sale to Covance Inc

...isition of clinical pharmacology and research company, Swiss Pharma Contract (SPC) by leading contract research organization, Covance Inc (NYSE: cvd ). Jina Ventures was the exclusive financial advisor to SPC in the transaction, which provides Covance with the facilities and services of Basel, S...

Covance Increases Early Clinical Footprint in Europe with Acquisition of Swiss-Based Early Clinical Development Site

... PRINCETON, N.J., March 13 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE: cvd ) announced today that it is expanding its clinical pharmacology footprint in Europe with the acquisition of Swiss Pharma Contract, a 50-bed clinical ...

Brooks Instrument's New Mass Flow Controller Series Is Immune to Pressure and Temperature Fluctuations

...flow control," stated Steve Kannengieszer, Director of Marketing, Mass Flow Products at Brooks Instrument. "Whether you are flowing gas to a cvd chamber, chemical research reactor, fuel cell test stand, or any other important flow control application, the quality of your results are only as goo...

Covance Purchases Equity Stake in Caprion Proteomics

...- BiomarkerCenter of Excellence Established in Greenfield, Indiana PRINCETON, N.J.,Dec. 16 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE: cvd ), a leading provider of drug development services, announced today that it has purchased a minority equity stake in Caprion Proteomics, the leading p...